1.83

0.00% +0.00

After Hours: 1.83

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is currently priced at $1.83, with a 24-hour trading volume of 1.20M. It has seen a +0.00% increased in the last 24 hours and a -8.50% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.82 pivot point. If it approaches the $1.86 resistance level, significant changes may occur.

Previous Close:

$1.83

Open:

$1.84

24h Volume:

1.20M

Market Cap:

$124.45M

Revenue:

$380.79M

Net Income/Loss:

$49.27M

P/E Ratio:

-1.4758

EPS:

-1.24

Net Cash Flow:

$10.68M

1W Performance:

+4.27%

1M Performance:

-8.50%

6M Performance:

-84.84%

1Y Performance:

-93.41%

1D Range:

$1.81

$1.87

52W Range:

$1.70

$27.99

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

617-682-0917

Address

43 Thorndike Street, Cambridge

Employee

Twitter

Next Earnings Date

2024-06-06

Latest SEC Filings

AMLX's Discussions on Twitter

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

Relyvrio's Failure Sparks NeuroSense ALS Development Changes - Pink Sheet

Pink Sheet

Amylyx Pharma director Quimi Daphne buys $9.4k in stock - Investing.com Australia

Investing.com Australia

Manufacturer to pull controversial ALS drug off the market after failed clinical trial - MSN

MSN

Amylyx Pharmaceuticals exec sells $19.7k in stock By Investing.com - Investing.com Australia

Investing.com Australia

Amylyx Pharma director Quimi Daphne buys $9.4k in stock By Investing.com - Investing.com

Investing.com

Amylyx Pharmaceuticals exec sells $19.7k in stock By Investing.com - Investing.com UK

Investing.com UK

Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data

Amylyx Pharmaceuticals Inc (AMLX) Revenue 2024

AMLX reported a revenue (TTM) of $380.79 million for the quarter ending December 31, 2023.

Amylyx Pharmaceuticals Inc (AMLX) Net Income 2024

AMLX net income (TTM) was $49.27 million for the quarter ending December 31, 2023, a +124.84% increase year-over-year.

Amylyx Pharmaceuticals Inc (AMLX) Cash Flow 2024

AMLX recorded a free cash flow (TTM) of $10.68 million for the quarter ending December 31, 2023, a +105.85% increase year-over-year.

Amylyx Pharmaceuticals Inc (AMLX) Earnings per Share 2024

AMLX earnings per share (TTM) was $0.70 for the quarter ending December 31, 2023, a +120.41% growth year-over-year.

Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Mazzariello Gina	Chief Legal Officer	May 15 '24	Sale	1.88	10,455	19,654	151,477
Quimi Daphne	Director	May 14 '24	Buy	1.89	2,750	5,184	2,750
Klee Justin B.	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	2,959,308
Cohen Joshua B	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	3,023,002
FRATES JAMES M	Chief Financial Officer	Mar 05 '24	Sale	18.73	1,792	33,560	134,784
Mazzariello Gina	Chief Legal Officer	Mar 05 '24	Sale	18.73	1,540	28,841	81,372
Mazzariello Gina	Chief Legal Officer	Feb 23 '24	Sale	18.76	2,838	53,231	46,245
Klee Justin B.	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,836,776
Cohen Joshua B	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,900,470
Yeramian Patrick D	Chief Medical Officer	Jan 09 '24	Sale	16.33	2,812	45,915	205,605

Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.